Published • loading... • Updated
OliX’s OLX501A Demonstrates Greater Visceral Fat Reduction Relative to a Global Comparator in Obese Non-Human Primates
Summary by HealthTech HotSpot
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
OliX’s OLX501A Demonstrates Greater Visceral Fat Reduction Relative to a Global Comparator in Obese Non-Human Primates
Head-to-head study in obese non-human primates showed a 29.2% reduction in visceral fat with OLX501A versus 10.0% with a global comparator, after adjustment for baseline values and food intake Robust and sustained pharmacodynamic activity supports the potential for a differentiated profile as an RNAi-based obesity therapy Data suggests the potential for selective fat reduction and more... The post OliX’s OLX501A Demonstrates Greater Visceral Fat…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
